the treatment of severe anemia related to end-stage renal disease with recombinant human erythropoietin ( r-huepo ; epogen , [ epoetin alfa ] amgen inc , thousand oaks , ca ) has been investigated in more than 1,500 hemodialysis patients worldwide .
C0700704
epogen
C0357126
epoetin alfa